Đang chuẩn bị liên kết để tải về tài liệu:
Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

After several exploratory and confirmatory clinical trials, the intralesional administration of human recombinant epidermal growth factor (hrEGF) has been approved for the treatment of advanced diabetic foot ulcers (DFU). | Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers